You are here: Industry Insights > Intra-Cellular Therapies

News List

Intra-Cellular Therapies Announces U.S. FDA Approval of Caplyta (lumateperone) for the Treatment of Bipolar Depression in Adults Drugs
December 27, 2021
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders...
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA for Bipolar Depression americanpharmaceuticalreview
February 25, 2021
Intra-Cellular Therapies has recently submitted supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for two indications for CAPLYTA (lumateperone): 1) as monotherapy; and 2) as adjunctive therapy with lithium or ...
Intra-Cellular Therapies Announces Positive Results from Bipolar Depression Treatment Study americanpharmaceuticalreview
September 14, 2020
Intra-Cellular Therapies announced positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or ...
Intra-Cellular Therapies Announces Availability of CAPLYTA for Schizophrenia americanpharmaceuticalreview
March 27, 2020
Intra-Cellular Therapies announced CAPLYTA (lumateperone) is now available to pharmacies in the U.S. CAPLYTA is an oral, once daily medicine approved for the treatment of schizophrenia in adults.